¶¶ÒõÂÃÐÐÉä

Commercialization activities throughÌýVenture Partners at ¶¶ÒõÂÃÐÐÉä Boulder had an economic impact ofÌý$8.7 billion nationally andÌý$5.1 billion in the state of Colorado over the last five years, according to a new report from the Leeds School of Business.

The Colorado BioScience Association (CBSA), which creates co-opportunity for Colorado’s life sciences community by championing a collaborative ecosystem and advocating for a supportive business climate, announces new leadership for its Board of Directors and welcomes new board members, including Hannah Nelson, associate director of licensing at Venture Partners at ¶¶ÒõÂÃÐÐÉä Boulder.

Venture Partners at ¶¶ÒõÂÃÐÐÉä Boulder and its partners across the Intermountain West once again demonstrated the power of university innovations atÌýDestination Startup®.

The University of Colorado's Ascent Deep Tech Accelerator has announced its 2026 startup teams. The selected companies span a wide range of disciplines, reflecting the depth and breadth of innovation emerging from ¶¶ÒõÂÃÐÐÉä’s research enterprise.

Destination Startup brings groundbreaking startups built on novel discoveries from top national labs and universities together with investors from throughout North America to catalyze real-world impact. This showcase demonstrates a powerful way to invest in and get funding for innovative research and translate it into impactful business ventures.

¶¶ÒõÂÃÐÐÉä Boulder Today—The University of Colorado (¶¶ÒõÂÃÐÐÉä) and Medtronic, a global leader in health care technology, have entered into a strategic research agreement to accelerate the development of transformative health technologies. ¶¶ÒõÂÃÐÐÉä was selected from a nationwide search for its strength in advancing disruptive innovation.

Colorado BioScience Association (CBSA)—The state’s life sciences ecosystem raised $3.2 billion in 2025, a record driven by significant mergers and acquisitions. The results demonstrate the durability of Colorado’s life sciences community as companies, investors, and research institutions operate amid economic, regulatory, and policy uncertainty.

The Embark Deep Tech Startup Creator pairs seasoned entrepreneurs with University of Colorado Boulder technologies to bring those breakthroughs to market to address urgent societal needs. Embark has launched its third cohort of Embark Startup Founders and will provide intellectual property rights, funding for the founders and their companies, startup accelerator programming support and investor introductions to launch startups with real-world impact.

In an ongoing effort to bridge a pervasive investment gap in innovation funding, the University of Colorado Boulder has awarded pre-seed funding to Illumen Therapeutics, developing cancer treatments based on discoveries from startup co-founder Roy Parker’s lab at ¶¶ÒõÂÃÐÐÉä Boulder.

The University of Colorado Boulder actively incubates and supports nonprofit and for-profit ventures with broad societal impact, from far-reaching educational and wellness tools to vaccine accessibility and water security.